Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) PT at $19.80

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $19.80.

Several research firms have weighed in on CATX. Oppenheimer cut their target price on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Bank of America initiated coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th.

Perspective Therapeutics Trading Down 1.8 %

Shares of CATX opened at $13.23 on Monday. Perspective Therapeutics has a 1 year low of $2.20 and a 1 year high of $19.05. The stock’s 50-day moving average is $13.81.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. As a group, equities analysts predict that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics in the 1st quarter valued at about $15,511,000. Affinity Asset Advisors LLC acquired a new stake in Perspective Therapeutics in the 1st quarter valued at approximately $6,069,000. Vanguard Group Inc. lifted its stake in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth approximately $3,951,000. Finally, WealthPLAN Partners LLC bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $1,695,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.